Evaluating Briquilimab for Allergic Asthma
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
This study is testing a new drug called briquilimab to see if it can help adults with allergic asthma breathe better and reduce their symptoms.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Jasper Therapeutics, Inc. Industry-sponsored |
| Drugs / interventions | briquilimab |
| Locations | 6 sites (Calgary, Alberta and 5 other locations) |
| Trial ID | NCT06592768 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and efficacy of briquilimab in individuals with allergic asthma using a double-blind, placebo-controlled design. Participants will receive a single dose of briquilimab or a placebo, and their responses will be assessed through an allergen challenge model. The study aims to determine the drug's impact on lung function and asthma symptoms while minimizing participant exposure. It targets adults aged 18 to 65 with stable allergic asthma and specific baseline criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with stable allergic asthma and a history of episodic wheeze and shortness of breath.
Not a fit: Patients with worsening asthma, respiratory infections, or other lung diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from allergic asthma.
How similar studies have performed: Previous studies have shown promise with similar approaches in treating allergic asthma, but the specific use of briquilimab is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women 18 to 65 years of age; stable, allergic asthma; history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline at least 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form; positive methacholine challenge at baseline (concentration of methacholine causing 20% decrease in FEV1 \[PC20\] PC20 ≤ 16 mg/mL or PD20 equivalent to ≤400µg); and positive skin-prick test and positive allergen-induced early and late airway bronchoconstriction to common aeroallergens. Exclusion Criteria: * Worsening of asthma or respiratory infection in the preceding 6 weeks; lung disease other than allergic asthma; prior treatment with a c-Kit inhibiting therapy; anaphylaxis to any parenterally administered biologics; use of asthma medications (note: intermittent doses of short-acting β2-agonist are allowed once weekly for relief of symptoms but prophylactic use for exercise is allowed as-needed); pregnant or lactating women; and women actively seeking pregnancy or who are not using adequate contraception.
Where this trial is running
Calgary, Alberta and 5 other locations
- University of Calgary — Calgary, Alberta, Canada (Recruiting)
- University of Alberta — Edmonton, Alberta, Canada (Recruiting)
- University of British Columbia — Vancouver, British Columbia, Canada (Recruiting)
- McMaster University — Hamilton, Ontario, Canada (Recruiting)
- University of Laval — Quebec City, Quebec, Canada (Recruiting)
- University of Saskatchewan — Saskatoon, Saskatchewan, Canada (Recruiting)
Study contacts
- Study coordinator: Jasper
- Email: clinicaltrials@jaspertx.com
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.